BACKGROUND: Despite their ease of use, lateral flow immunoassays (LFIAs) often suffer from poor quantitative discrimination and low analytical sensitivity. We explored the use of a novel class of europium chelate-loaded silica nanoparticles as labels to overcome these limitations. METHODS: Antibodies were covalently conjugated onto europium chelate-loaded silica nanoparticles with dextran as a linker. The resulting conjugates were used as labels in LFIA for detection of hepatitis B surface antigen (HBsAg). We performed quantification with a digital camera and Adobe Photoshop software.Wealso used 286 clinical samples to compare the proposed method with a quantitative ELISA. RESULTS: A detection limit of 0.03 μg/L was achieved, which was 100 times lower than the colloidal gold-based LFIAs and lower than ELISA. A precise quantitative dose-response curve was obtained, and the linear measurement range was 0.05-3.13 μg/L, within which the CVs were 2.3%-10.4%. Regression analysis of LFIA on ELISA results gave: log (LFIA) = -0.14 log (ELISA) + 1.03 μg/L with r = 0.99 for the quantification of HBsAg in 35 positive serum samples. Complete agreement was observed for the qualitative comparison of 286 clinical samples assayed with LFIA and ELISA. CONCLUSIONS: Europium chelate-loaded silica nanoparticle labels have great potential to improve LFIAs, making them useful not only for simple screening applications but also for more sensitive and quantitative immunoassays.
CITATION STYLE
Xia, X., Xu, Y., Zhao, X., & Li, Q. (2009). Lateral flow immunoassay using europium chelate-loaded silica nanoparticles as labels. Clinical Chemistry, 55(1), 179–182. https://doi.org/10.1373/clinchem.2008.114561
Mendeley helps you to discover research relevant for your work.